Chemistry:Otlertuzumab

From HandWiki
Short description: Monoclonal antibody
Otlertuzumab
Monoclonal antibody
Type?
SourceHumanized (from mouse)
TargetCD37
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
FormulaC4660H7136N1246O1452S30
Molar mass104809.42 g·mol−1

Otlertuzumab (TRU‐016) is a humanized monoclonal antibody that targets CD37[1] designed for the treatment of cancer.[2]

This drug was developed by Emergent BioSolutions and has been in clinical trials for lymphoma and Chronic Lymphocytic Leukemia (CLL)[3]

References

  1. "Anti-CD37 targeted immunotherapy of B-Cell malignancies". Biotechnology Letters 40 (11–12): 1459–1466. December 2018. doi:10.1007/s10529-018-2612-6. PMID 30293139. 
  2. "Otlertuzumab". Statement On A Nonproprietary Name Adopted By The USAN Council. American Medical Association. http://www.ama-assn.org/resources/doc/usan/otlertuzumab.pdf. 
  3. "Otlertuzumab". ClinicalTrails.gov. U.S. National Library of Medicine. https://clinicaltrials.gov/ct2/results?cond=&term=Otlertuzumab&cntry=&state=&city=&dist=&Search=Search.